In turn, the luminal B (ER+/PgR+/HER2+ or HER2− with high Ki67) subtype is responsible for 10–20% of all cancer cases, has higher relapse rate, histological grade, proliferative index, and the lower relapse survival rate [10,11,12]. Here, ERBB2 is linked to cancer.